Literature DB >> 2359

Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey.

M Hutchinson, H W Kosterlitz, F M Leslie, A A Waterfield.   

Abstract

1 Four benzomorphans which have potent antinociceptive activity in the hot-plate and writhing tests in the mouse but do not suppress or precipitate withdrawal symptoms in the morphine-dependent monkey, have been examined for their pharmacological actions in the guinea-pig ileum and mouse vas deferens. 2 In the guinea-pig ileum their agonist potencies are 1.5 to 400 times greater than that of normorphine of morphine whereas in the mouse vas deferens their potencies relative to morphine are 0.3 to 100. They exhibit no antagonist activity in either preparation. Benzomorphans which substitute for morphine in the morphine-dependent monkey do not show such differences between their relative potencies in the guinea-pig ileum and mouse vas diferens. 3 The relative potencies of the four benzomorphans to inhibit stereospecific [3H]-dihydromorphine binding by membrane fragments from rat brain, are more closely related to their relative agonist potencies in the mouse vas deferens than to those found in the guinea-pig ileum. 4 In order to antagonize the agonist actions of these benzomorphans, naloxone is required in concentrations which are 3 to 7 times higher than those needed for the antagonism of normorphine or morphine or of benzomorphans which suppress abstinence in morphine-dependent monkeys. 5 It may be possible to use the three assays, namely, ratio of relative agonist potency in mouse vas deferens to that in guinea-pig ileum, ratio of relative agonist potency to relative affinity to opiate receptors and the concentration of nalozone required for antagonism, for the prediction of the potential of new compounds to produce physical dependence.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 2359      PMCID: PMC1666732          DOI: 10.1111/j.1476-5381.1975.tb07430.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  Purification and properties of enkephalin - the possible endogenous ligand for the morphine receptor.

Authors:  J Hughes; T Smith; B Morgan; L Fothergill
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

Review 2.  In vitro models in the study of structure-activity relationships of narcotic analgesics.

Authors:  H W Kosterlitz; A A Waterfield
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

3.  Contribution of 'receptor' affinity to analgesic potency.

Authors:  L Terenius
Journal:  J Pharm Pharmacol       Date:  1974-02       Impact factor: 3.765

4.  Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain.

Authors:  L Terenius
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

5.  Some thoughts on the significance of enkephalin, the endogenous ligand.

Authors:  H W Kosterlitz; J Hughes
Journal:  Life Sci       Date:  1975-07-01       Impact factor: 5.037

6.  Structure-activity relationships in narcotic antagonists with N-furylmethyl substituents.

Authors:  H Merz; A Langbein; K Stockhaus; G Walther; H Wick
Journal:  Adv Biochem Psychopharmacol       Date:  1973

7.  Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics.

Authors:  J Hughes; H W Kosterlitz; F M Leslie
Journal:  Br J Pharmacol       Date:  1975-03       Impact factor: 8.739

8.  Properties of opiate-receptor binding in rat brain.

Authors:  C B Pert; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

9.  Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone).

Authors:  H W Kosterlitz; A J Watt
Journal:  Br J Pharmacol Chemother       Date:  1968-06

10.  Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain.

Authors:  A Goldstein; L I Lowney; B K Pal
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

View more
  30 in total

1.  Comparison of the receptor binding characteristics of opiate agonists interacting with mu- or kappa-receptors.

Authors:  H W Kosterlitz; F M Leslie
Journal:  Br J Pharmacol       Date:  1978-12       Impact factor: 8.739

2.  Control of guinea pig intestinal electrolyte secretion by a delta-opiate receptor.

Authors:  J F Kachur; R J Miller; M Field
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

3.  A classification of opiate receptors that mediate antinociception in animals.

Authors:  M B Tyers
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

4.  Changes in locomotor activity and naloxone-induced jumping in mice produced by WIN 35, 197-2 (ethylketazocine) and morphine.

Authors:  P Tepper; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1978-07-06       Impact factor: 4.530

5.  Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

6.  Proceedings of the British Pharmacological Society. Liverpool, 6th-8th April, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

7.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

8.  YFa and analogs: investigation of opioid receptors in smooth muscle contraction.

Authors:  Krishan Kumar; Ritika Goyal; Annu Mudgal; Anita Mohan; Santosh Pasha
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

9.  Inhibition of [3H]-naloxone binding by opiate agonists [proceedings].

Authors:  H W Kosterlitz; F M Leslie
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

Review 10.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.